InvestorsHub Logo
Followers 604
Posts 24107
Boards Moderated 3
Alias Born 12/06/2009

Re: None

Thursday, 08/24/2017 2:00:48 AM

Thursday, August 24, 2017 2:00:48 AM

Post# of 27643
The entire cold chain vaccine development process is dependent on MYMX.

The purpose of the project MACIVIVA is to develop Vaccine based tablets that are not required to be put in cold storage so that they can have longer storage life and be transferred and delivered around the world efficiently.

freeze dried zydis tablets are designed to store a manufactured vaccine which dissolves on the human tongue within 3 seconds.

Mymetics is the partner that is required in Maciviva to produce the virosome membranes. They have developed the virosome to be completely able to be packaged into freeze dried soluble tablets.

Catalent (NYSE) is another partner on the Maciviva project... they are responsible for the tablets..

but none of which is possible without Mymetics virosome membranes.. These membranes are able to "DELIVER" the vaccine to the human effectively.

http://www.catalent.com/index.php/news-events/news/Catalent-Awarded-Grant-As-Part-Of-Vaccine-Research-Consortium

"No More Pricks"



http://www.maciviva.eu

The MACIVIVA project ends in November.

This will change human history. forever. I expect Sanofi to buy out Mymetics for anywhere in the range of 600 million to 2.5 billion dollars.. this is an estimate of lower end numbers in my opinion.

just my opinion.

MYMX could be bought out for anywhere from 1-5 dollars per share imo.

Sanofi will make a move on it this year imo.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMX News